MA40869A - PHARMACEUTICAL COMBINATIONS OF VILDAGLIPTIN AND PPAR AGONISTS - Google Patents
PHARMACEUTICAL COMBINATIONS OF VILDAGLIPTIN AND PPAR AGONISTSInfo
- Publication number
- MA40869A MA40869A MA040869A MA40869A MA40869A MA 40869 A MA40869 A MA 40869A MA 040869 A MA040869 A MA 040869A MA 40869 A MA40869 A MA 40869A MA 40869 A MA40869 A MA 40869A
- Authority
- MA
- Morocco
- Prior art keywords
- vildagliptin
- pharmaceutical combinations
- ppar agonists
- ppar
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR201412671 | 2014-10-30 | ||
TR201413046 | 2014-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40869A true MA40869A (en) | 2017-09-05 |
Family
ID=54601735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040869A MA40869A (en) | 2014-10-30 | 2015-10-27 | PHARMACEUTICAL COMBINATIONS OF VILDAGLIPTIN AND PPAR AGONISTS |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3212185A1 (en) |
MA (1) | MA40869A (en) |
WO (1) | WO2016066668A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220175721A1 (en) * | 2019-02-13 | 2022-06-09 | Cadila Healthcare Limited | Treatment for polycystic ovarian syndrome (pcos) |
WO2020183379A1 (en) * | 2019-03-11 | 2020-09-17 | Cadila Healthcare Limited | Novel salts, crystalline forms and premix of hypolipidemic agent |
TR202009946A2 (en) * | 2020-06-25 | 2022-01-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A STABLE COMBINATION WITH VILDAGLIPTIN AND METFORMIN HCI |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018125A1 (en) | 1993-12-27 | 1995-07-06 | Japan Tobacco Inc. | Isoxazolidinedione derivative and use thereof |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
US7192970B2 (en) * | 2002-11-26 | 2007-03-20 | Chipscreen Biosciences, Ltd. | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity |
US20060270722A1 (en) * | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
JP2009522374A (en) * | 2006-01-06 | 2009-06-11 | ノバルティス アクチエンゲゼルシャフト | Use of vildagliptin for the treatment of diabetes |
TR201101809A1 (en) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin and glimepiride combinations. |
EP2468268B1 (en) * | 2010-12-21 | 2017-12-13 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combination composition of vildagliptin and gliclazide |
US20140302150A1 (en) * | 2011-09-07 | 2014-10-09 | Umit Cifter | Dpp-iv inhibitor formulations |
WO2014195967A2 (en) * | 2013-05-30 | 2014-12-11 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
-
2015
- 2015-10-27 MA MA040869A patent/MA40869A/en unknown
- 2015-10-28 EP EP15797264.7A patent/EP3212185A1/en not_active Withdrawn
- 2015-10-28 WO PCT/EP2015/074939 patent/WO2016066668A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2016066668A1 (en) | 2016-05-06 |
EP3212185A1 (en) | 2017-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244000B (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MA49715A (en) | OLIGOMERS AND CONJUGATES OF OLIGOMERS | |
DK3142637T3 (en) | KERATIN TREATMENT FORMULATIONS AND METHODS | |
MA41028A (en) | METHODS AND FORMULATIONS FOR THE TREATMENT OF VASCULAR EYE PATHOLOGIES | |
ZA202003664B (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
MA54716A (en) | REDUCTION OF THE VISCOSITY OF PHARMACEUTICAL FORMULATIONS | |
PL3240777T3 (en) | Arginase inhibitors and their therapeutic applications | |
MA46867A (en) | PHARMACEUTICAL FORMULATIONS | |
IL280690A (en) | Pharmaceutical compositions comprising dgla and use of same | |
MA45187A (en) | PHARMACEUTICAL COMBINATIONS | |
IL250289B (en) | Angiopoietin-like 4 antibodies and methods of use | |
DK3137873T3 (en) | VISCOMETER AND METHODS OF USE THEREOF | |
FR3022139B1 (en) | NEW COMPOSITIONS FOR THE TREATMENT OF SKIN FLAVORS AND ROSACEA | |
MA40869A (en) | PHARMACEUTICAL COMBINATIONS OF VILDAGLIPTIN AND PPAR AGONISTS | |
MA42130A (en) | COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES | |
MA40868A (en) | PHARMACEUTICAL COMBINATIONS OF SITAGLIPTIN AND PPAR AGONISTS | |
FR3016128B1 (en) | HEAD OF DISTRIBUTION AND APPLICATION. | |
MA40596A (en) | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A BCL-2 INHIBITOR | |
ES1135310Y (en) | Simplified and perfected bearing | |
TH1501006461A (en) | Derivatives of dolastatin 10 and auristatins | |
TH1601000571A (en) | Compounds showing medicinal effects and methods of their use | |
TH1601002731A (en) | N-benzyl tryptantrin derivatives and methods of their preparation and applications. | |
TH1601000722A (en) | New compounds and their pharmaceutical compositions for treatment cystic fibrosis | |
TH1601003662A (en) | Displaced piperidinyltetrahydroquinoline and their use as alpha-2C adrenoreceptor antagonists | |
TH1501005057A (en) | Processes and intermediates for drug preparation |